Overview

Study of Phosphate Levels in Patients With Chronic Kidney Disease

Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.
Phase:
Phase 2
Details
Lead Sponsor:
Vifor Inc.
Vifor Pharma
Treatments:
Iron
Sevelamer